ArticleMethods in molecular biology (Clifton, N.J.)2017
Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.
Article in Methods in molecular biology (Clifton, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Immune Protection Effect of an OmpC-Recombinant T4 Bacteriophage Vaccine Against Infection Caused by Extraintestinal PathogenicVaccines · 2026Article
- In situ structures of the portal-neck-tail complex of bacteriophage T4 inform a viral genome positioning mechanism.Nature communications · 2026Article
- An Update on Vaccines AgainstPathogens (Basel, Switzerland) · 2025Review
- Chemically Tagging Cargo for Specific Packaging inside and on the Surface of Virus-like Particles.ACS nano · 2024Article
- Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Landscape of New Nuclease-Containing Antiphage Systems in Escherichia coli and the Counterdefense Roles of Bacteriophage T4 Genome Modifications.Journal of virology · 2023Article
- Engineering T4 Bacteriophage forACS synthetic biology · 2021Article
- Bacteriophage Capsid Modification by Genetic and Chemical Methods.Bioconjugate chemistry · 2021Review
- Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.Frontiers in immunology · 2021Article
- Specific Integration of Temperate Phage Decreases the Pathogenicity of Host Bacteria.Frontiers in cellular and infection microbiology · 2020Article
- Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.Advanced drug delivery reviews · 2019Review
- Genetic Engineering of Bacteriophages Against Infectious Diseases.Frontiers in microbiology · 2019Review
- Article
- Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9.Science advances · 2018Article
- Engineering of Bacteriophage T4 Genome Using CRISPR-Cas9.ACS synthetic biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Protein-based subunit vaccines represent a safer alternative to the whole pathogen in vaccine development. However, limitations of physiological instability and low immunogenicity of such vaccines demand an efficient delivery system to stimulate robust immune responses. The bacteriophage T4 capsid-based antigen delivery system can robustly elicit both humoral and cellular immune responses without any adjuvant. Therefore, it offers a strong promise as a novel antigen delivery system. Currently Bacillus anthracis, the causative agent of anthrax, is a serious biothreat agent and no FDA-approved anthrax vaccine is available for mass vaccination. Here, we describe a potential anthrax vaccine using a T4 capsid platform to display and deliver the 83 kDa protective antigen, PA, a key component of the anthrax toxin. This T4 vaccine platform might serve as a universal antigen delivery system that can be adapted to develop vaccines against any infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.